SciBase Holding AB
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Pia Renaudin
- Full Time Employees
- 46
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Landsvägen 39 Stockholm AB Sweden 172 63
- IPO Date
- Jun 2, 2015
- Website
- scibase.com
- Similar Companies
- Business
- SciBase Holding AB (publ) operates as a medical technology enterprise, concentrating on the creation and commercialization of instruments designed for the identification of skin cancer and other dermatological conditions across global markets. The company's core offering is the Nevisense platform, which includes devices such as Nevisense and Nevisense Go. This advanced point-of-care system integrates Electrical Impedance Spectroscopy (EIS) with augmented intelligence (AI) to enhance diagnostic precision. Its applications span crucial areas like the early detection of melanoma, assessment of non-melanoma skin cancers, and comprehensive evaluation of skin barrier function, the latter also supporting research and conditions such as atopic dermatitis. SciBase employs a revenue model where customers initially acquire the diagnostic device and then routinely purchase proprietary disposable electrodes. Recently, SciBase has expanded its reach through strategic partnerships, including an extended collaboration with Castle Biosciences aimed at developing new dermatological tests, as well as agreements with Unified Health in Los Angeles and Kilabs for market entry into Italy and the United Arab Emirates. Founded in 1998, SciBase Holding AB (publ) maintains its headquarters in Stockholm, Sweden, and continues to advance its position in dermatological diagnostics based on over two decades of research.
Company News
SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier Study
SciBase Submits FDA 510(k) to Expand Nevisense into the Largest Skin Cancer Market
First Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase
SciBase Announces New Research Highlighting Nevisense's Potential in Detecting Age-Related Skin Barrier Changes
SciBase Announces New Research Highlighting Nevisense's Potential in Detecting Age-Related Skin Barrier Changes
SciBase Announces New Research Highlighting Nevisense's Potential in Detecting Age-Related Skin Barrier Changes
SciBase's Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma
A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns
SciBase Expands Its Intellectual Property Portfolio to include the analysis of the epithelial skin barrier with New European Patent